<DOC>
	<DOCNO>NCT00241254</DOCNO>
	<brief_summary>Preliminary not-controlled clinical study efficacy monthly intravenous cyclophosphamide administration secondary progressive multiple sclerosis report encouraging result , randomize control trial conduct far . The primary objective trial evaluate efficacy IV cyclophosphamide compare IV methylprednisolone administer every 4 week 1 year every 8 week 1 year , delay confirm disability deterioration assess Expanded Disability Status Scale ( EDSS ) patient secondary progressive multiple sclerosis . The secondary objective evaluate safety , tolerability efficacy 2 year Multiple Sclerosis Functional Composite ( MSFC ) , percentage patient disability deterioration ( EDSS ) number relapse . An intention-to-treat statistical analysis carry .</brief_summary>
	<brief_title>Efficacy Cyclophosphamide Versus Methylprednisolone Patients With Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description>Background Preliminary not-controlled clinical study efficacy monthly intravenous cyclophosphamide administration secondary progressive multiple sclerosis report encouraging result , randomize control trial conduct far . A slight efficacy Methylprednisolone report indication . Objectives The primary objective evaluate efficacy IV cyclophosphamide prevention disability deterioration patient secondary progressive multiple sclerosis . The secondary objective evaluate safety , tolerability efficacy IV cyclophosphamide Multiple Sclerosis Functional Composite ( MSFC ) number relapse . Study design Randomized double-blind two-arm control trial . Intervention Experimental group : IV cyclophosphamide infusion administer every 4 week 1 year every 8 week 1 year . Control group : IV methylprednisolone infusion administer every 4 week 1 year every 8 week 1 year . Outcomes Primary outcome : delay disability deterioration assess Expanded Disability Status Scale ( EDSS : 0.5 1 point increase , depend baseline score ) evaluate every 4 week one year , every 8 week one year . Secondary outcome : proportion patient disability deterioration ( EDSS : 0.5 1 point increase , depend baseline score ) , Multiple Sclerosis Functional Composite ( MSFC ) Z score MSFC three component , number MS relapse , proportion patient adverse event delay occurrence adverse event , quality life questionnaire . - Quality life questionnaires - Disability self-assessment questionnaire Main time assessment : 2 year . Sample size 360 patient Statistical analysis Intention-to-treat analysis .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Multiple sclerosis ( MS ) subject ( Mc Donald et al criterion ) , Aged 18 65 Diagnosis secondary progressive MS ( Lublin Reingold criterion ) Progressive deterioration phase least 6 month le 4 year . Reduction walk capacity increase EDSS ascribe consequence relapse ( least 0.5 point ) last 12 month EDSS 4.0 6.5 included Female participating must use contraceptive study drug Written inform consent Patient protect French social security system Others diseases interfere MS treatment Recent history ( within previous 2 year ) drug alcohol abuse . Patients psychiatric illness unable provide write , informed consent prior test protocol Hemorrhagic cystitis Pregnant lactate woman Known allergy cyclophosphamide , corticoid particular methylprednisolone Persistent infectious disease Patients bladder permanent catheterization Known history cardiac arrhythmia methylprednisolone intravenous treatment Abnormal screening/baseline blood test exceed limit define : Hb &lt; 9g/dl Total white blood cell count less 3 000/mm3 lymphocyte count less 900/ mm3 Platelet count less 125 000/mm3 Gastric duodenal ulcer evolution Gut diverticulosis Diabetes mellitus Known history active hepatitis ( ASAT &gt; 3 X ULN ) Known history renal failure ( creatinine level &gt; 180 Âµmol/L ) Psychosis Current past ( &lt; 3 month ) participation another drug trial Prior use cyclophosphamide , lymphoid irradiation , monoclonal antibody anti CD4 anti CD52 antiVLA4 therapy , cladribine ou cyclosporine A Other clinical type MS : Secondary progressive phase evolve 4 year ; Remittent type MS without progression relapse ; Primary progressive type MS Use interferon beta , methotrexate imurel month prior study . Treatment intravenous monthly corticoid year prior study . Treatment corticoid ( 3 5 day ) 2 month prior study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Multiple Sclerosis , Chronic Progressive</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Methylprednisolone</keyword>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Double-Blind Study</keyword>
</DOC>